The European Medicines Agency's pharmacovigilance committee, PRAC, has recommended further restrictions to avoid exposure of babies in the womb to valproate-containing medicines, which are used to treat epilepsy, bipolar disorder and migraine.
The recommendations, which include a call to introduce a pregnancy prevention program, apply to the use of valproate medicines in...




